Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 13/20 | 0.68 |
| ▸ | MEN1 | O00255 | 12/20 | 0.68 |
| ▸ | UGCG | Q16739 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | MTOR | P42345 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | GMNN | O75496 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17636013 | 0.99 | KMT2A (0.70) | KMT2AMEN1UGCGTP53MAPT | |
| SCHEMBL5075622 | 0.99 | KMT2A (0.70) | KMT2AMEN1UGCGTP53MAPT | |
| SCHEMBL7683399 | 0.89 | UGCG (0.69) | KMT2AMEN1UGCGTP53MAPT | |
| SCHEMBL7692580 | 0.83 | KMT2A (0.53) | KMT2AMEN1UGCGTP53MAPT | |
| SCHEMBL23845860 | 0.81 | UGCG (1.00) | KMT2AMEN1UGCGTP53MAPT | |
| SCHEMBL137622 | 0.81 | UGCG (1.00) | KMT2AMEN1UGCGTP53MAPT | |
| SCHEMBL12000798 | 0.81 | UGCG (1.00) | KMT2AMEN1UGCGTP53MAPT | |
| SCHEMBL723342 | 0.81 | UGCG (1.00) | KMT2AMEN1UGCGTP53MAPT | |
| SCHEMBL295573 | 0.81 | UGCG (1.00) | KMT2AMEN1UGCGTP53MAPT | |
| SCHEMBL14304968 | 0.81 | UGCG (1.00) | KMT2AMEN1UGCGTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1091745-B1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS | CHILDREN S HOSPITAL LOS ANGELE (US) | 2008-10-01 | — | — | EP | claimed |
| US-20190117590-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | TEXAS TECH UNIVERSITY SYSTEM | 2019-04-25 | — | — | US | disclosed |
| EP-2669267-B1 | Compositions and methods for treating hyperproliferative disorders | TEXAS TECH UNIV (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-1722771-B1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING AN INFLAMMATORY RESPONSE | UNIV MCGILL (CA) | 2014-04-23 | — | — | EP | disclosed |
| EP-2669267-A1 | Compositions and methods for treating hyperproliferative disorders | TEXAS TECH UNIVERSITY (US) | 2013-12-04 | — | — | EP | disclosed |
| US-20130217691-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | TEXAS TECH UNIVERSITY SYSTEM (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2501672-A2 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS | TEXAS TECH UNIVERSITY (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-1641922-B1 | NEWLY IDENTIFIED CHOLINEPHOSPHOTRANSFERASES AND ETHANOLAMINEPHOSPHOTRANSFERASES | UNIV UTRECHT HOLDING BV (NL) | 2012-09-26 | — | — | EP | disclosed |
| US-8143313-B2 | Compositions and methods for preventing or treating an inflammatory response | MCGILL UNIVERSITY (CA) | 2012-03-27 | — | — | US | disclosed |
| US-20110152267-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | TEXAS TECH UNIVERSITY SYSTEM | 2011-06-23 | — | — | US | disclosed |
| WO-2000000207-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS | CHILDREN'S HOSPITAL OF LOS ANGELES (US) | 2000-01-06 | — | — | WO | disclosed |
| EP-0782631-A4 | TREATMENT OF PLASMODIUM | UNIV LELAND STANFORD JUNIOR (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5849326-A | Method for treating neuronal diseases via administration of 2-acylaminopropanol derivatives | SEIKAGAKU CORPORATION (JP) | 1998-12-15 | — | — | US | disclosed |
| US-5707649-A | USING A 2-ACYLAMINOPROPANOL DERIVATIVE | SEIKAGAKU CORPORATION (JP) | 1998-01-13 | — | — | US | disclosed |
| EP-0782631-A1 | TREATMENT OF PLASMODIUM | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1997-07-09 | — | — | EP | disclosed |
| EP-0720852-A1 | REMEDY FOR NERVOUS DISEASES | SEIKAGAKU CORPORATION (JP) | 1996-07-10 | — | — | EP | disclosed |
| WO-1996009405-A1 | TREATMENT OF PLASMODIUM | THE BOARD OF TRUSTEES OF LELAND STANFORD, JUNIOR UNIVERSITY (US) | 1996-03-28 | — | — | WO | disclosed |
| US-5302609-A | Administering synthetase inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-04-12 | — | — | US | disclosed |
| US-5041441-A | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1991-08-20 | — | — | US | disclosed |
| US-5041441-A | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1991-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117590-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | SGMS1, S1PR1, SPHK1 | KMT2A 2285/4885MEN1 665/4885UGCG 18/4885 |
| US-20110152267-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | SGMS1, S1PR1, SPHK1 | KMT2A 2285/4885MEN1 665/4885UGCG 18/4885 |
| US-20130217691-A1 | Compositions and Methods for Treating Hyperproliferative Disorders | SGMS1, S1PR1, SPHK1 | KMT2A 2285/4885MEN1 665/4885UGCG 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.